Compare NOVT & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOVT | TVTX |
|---|---|---|
| Founded | 1968 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.3B |
| IPO Year | 1999 | 2013 |
| Metric | NOVT | TVTX |
|---|---|---|
| Price | $168.75 | $63.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | ★ $144.00 | $40.62 |
| AVG Volume (30 Days) | 412.9K | ★ 1.6M |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $521,290,000.00 | N/A |
| Revenue This Year | $8.61 | $44.76 |
| Revenue Next Year | $6.57 | $35.51 |
| P/E Ratio | $203.15 | ★ N/A |
| Revenue Growth | ★ 35.49 | N/A |
| 52 Week Low | $98.27 | $17.05 |
| 52 Week High | $176.38 | $66.24 |
| Indicator | NOVT | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.45 | 65.04 |
| Support Level | $146.45 | $53.76 |
| Resistance Level | $167.79 | $66.24 |
| Average True Range (ATR) | 6.35 | 2.56 |
| MACD | 1.97 | 0.30 |
| Stochastic Oscillator | 74.05 | 75.27 |
Novanta Inc supplies core technology solutions to medical, life science, and advanced industrial OEMs, leveraging proprietary expertise in precision medicine, precision manufacturing, robotics and automation, and advanced surgery. It has two segments: Automation Enabling Technologies and Medical Solutions. Automation Enabling Technologies, which generates the majority of revenue, provides laser beam steering and scanning solutions, laser sources, and robotic and precision motion technologies. The Medical Solutions segment provides medical-grade technologies, including medical insufflators, endoscopic pumps, and integrated operating room technologies. The company operates in the United States, Germany, and other markets, with revenue generated from the United States.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.